An Antibody Attack against Body Wasting in Cancer

Maria Rohm; Stephan Herzig

doi:10.1016/j.cmet.2020.08.003

An Antibody Attack against Body Wasting in Cancer

Cell Metab. 2020 Sep 1;32(3):331-333. doi: 10.1016/j.cmet.2020.08.003.

Authors

Maria Rohm¹, Stephan Herzig²

Affiliations

¹ Institute for Diabetes and Cancer (IDC), Helmholtz Munich, Neuherberg, Germany; Joint Heidelberg-IDC Transnational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.
² Institute for Diabetes and Cancer (IDC), Helmholtz Munich, Neuherberg, Germany; Joint Heidelberg-IDC Transnational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany; Chair Molecular Metabolic Control, Medical Faculty, Technical University Munich, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany. Electronic address: [email protected].

PMID: 32877689
DOI: 10.1016/j.cmet.2020.08.003

Abstract

Cachexia is a devastating, non-curable condition in many cancer patients that is marked by severe wasting of the muscle and fat tissue. Its prevention has been hampered by an insufficient knowledge of the underlying molecular mechanism(s) that lead to its pathogenesis. Suriben et al. (2020) now report the development and characterization of an antagonistic antibody for the previously identified GDF15-GFRAL axis that efficiently blocks tumor-induced body wasting in experimental animals.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adipose Tissue
Animals
Cachexia* / etiology
Growth Differentiation Factor 15
Humans
Mice
Neoplasms* / complications

Substances

GDF15 protein, human
Growth Differentiation Factor 15